Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Sept 24 (Reuters) — MediciNova Inc: Medicinova Announces Completion Of Last Patient, Last Visit In The Double-blind Portion Of The Phase 2b/3 Combat-als Trial Of Mn-166 (Ibudilast) Medicinova - Topline Results From Double-blind Portion Expected By End Of 2026 Source text:... Further company coverage: MNOV.O (Reuters.Br
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the dou…
MNOV - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)